Evaluation of patient-reported outcome assessment tools for lung cancer: protocol for a systematic review of measurement properties.
[OBJECTIVE] The objective of this review will be to appraise the measurement properties of patient-reported outcome assessment tools for lung cancer.
APA
Liang Y, Du Y, et al. (2026). Evaluation of patient-reported outcome assessment tools for lung cancer: protocol for a systematic review of measurement properties.. JBI evidence synthesis. https://doi.org/10.11124/JBIES-25-00280
MLA
Liang Y, et al.. "Evaluation of patient-reported outcome assessment tools for lung cancer: protocol for a systematic review of measurement properties.." JBI evidence synthesis, 2026.
PMID
41923706
Abstract
[OBJECTIVE] The objective of this review will be to appraise the measurement properties of patient-reported outcome assessment tools for lung cancer.
[INTRODUCTION] Patients with lung cancer manifest varying degrees of physical and psychosocial symptoms attributable to disease pathology and treatment-related complications, which significantly impair their quality of life. Although a few patient-reported outcome assessment tools are available for lung cancer, a comprehensive and standardized comparative analysis of their measurement properties is notably lacking.
[ELIGIBILITY CRITERIA] Eligible studies will include patients aged ≥18 years who are diagnosed with lung cancer at any disease stage (I-IV), regardless of treatment modality (eg, surgery, pharmacotherapy, chemotherapy, radiotherapy, neoadjuvant therapy, palliative care). Empirical studies that examine the development or validation of patient-reported outcome measures for patients with lung cancer will be considered if they evaluate at least 1 measurement property (eg, reliability, validity, responsiveness).
[METHODS] The following databases will be searched: PubMed, Web of Science Core Collection, CINAHL (EBSCOhost), Cochrane Library, Embase (Ovid), PsycINFO (Ovid), CNKI, Wanfang, SINOMED, and Weipu. To minimize publication bias and identify unpublished studies, gray literature sources will also be explored, including unpublished agency reports, professional organization websites, and dissertation/thesis databases, etc. Two reviewers will independently conduct study selection and data extraction. Methodological quality appraisal, synthesis of the quality of PROMs, and evidence quality grading will be conducted by 2 reviewers, in strict accordance with the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) methodology.
[REVIEW REGISTRATION] PROSPERO CRD420251028373.
[INTRODUCTION] Patients with lung cancer manifest varying degrees of physical and psychosocial symptoms attributable to disease pathology and treatment-related complications, which significantly impair their quality of life. Although a few patient-reported outcome assessment tools are available for lung cancer, a comprehensive and standardized comparative analysis of their measurement properties is notably lacking.
[ELIGIBILITY CRITERIA] Eligible studies will include patients aged ≥18 years who are diagnosed with lung cancer at any disease stage (I-IV), regardless of treatment modality (eg, surgery, pharmacotherapy, chemotherapy, radiotherapy, neoadjuvant therapy, palliative care). Empirical studies that examine the development or validation of patient-reported outcome measures for patients with lung cancer will be considered if they evaluate at least 1 measurement property (eg, reliability, validity, responsiveness).
[METHODS] The following databases will be searched: PubMed, Web of Science Core Collection, CINAHL (EBSCOhost), Cochrane Library, Embase (Ovid), PsycINFO (Ovid), CNKI, Wanfang, SINOMED, and Weipu. To minimize publication bias and identify unpublished studies, gray literature sources will also be explored, including unpublished agency reports, professional organization websites, and dissertation/thesis databases, etc. Two reviewers will independently conduct study selection and data extraction. Methodological quality appraisal, synthesis of the quality of PROMs, and evidence quality grading will be conducted by 2 reviewers, in strict accordance with the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) methodology.
[REVIEW REGISTRATION] PROSPERO CRD420251028373.
같은 제1저자의 인용 많은 논문 (5)
- Application of Diced Autologous Rib Cartilage for Paranasal Augmentation in Cleft Nose.
- Dosimetric comparison of the shoulder region between paired photon and proton plans in breast cancer patients.
- [Corrigendum] PRIMA‑1 inhibits growth of breast cancer cells by re‑activating mutant p53 protein.
- Remodeling the tumor dormancy ecosystem to prevent recurrence and metastasis.
- A Dual-Threshold Strategy Enables Reliable Biopsy-Free Diagnosis of High-Risk Prostate Cancer.